Sørensen, B; Susrud, A; Dalgleish, AG
(2020)
Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity.
QRB Discovery, 1.
e6.
ISSN 2633-2892
https://doi.org/10.1017/qrd.2020.8
SGUL Authors: Dalgleish, Angus George
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
|
|
PDF
Accepted Version
Available under License Creative Commons Attribution. Download (808kB) | Preview |
Abstract
This study presents the background, rationale and method of action of Biovacc-19, a candidate vaccine for corona virus disease 2019 (Covid-19), now in advanced preclinical development, which has already passed the first acute toxicity testing. Unlike conventionally developed vaccines, Biovacc-19’s method of operation is upon nonhuman-like (NHL) epitopes in 21.6% of the composition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)’s spike protein, which displays distinct distributed charge including the presence of a charged furin-like cleavage site. The logic of the design of the vaccine is explained, which starts with empirical analysis of the aetiology of SARS-CoV-2. Mistaken assumptions about SARS-CoV-2’s aetiology risk creating ineffective or actively harmful vaccines, including the risk of antibody-dependent enhancement. Such problems in vaccine design are illustrated from past experience in the human immunodeficiency viruses domain. We propose that the dual effect general method of action of this chimeric virus’s spike, including receptor binding domain, includes membrane components other than the angiotensin-converting enzyme 2 receptor, which explains clinical evidence of its infectivity and pathogenicity. We show the nonreceptor dependent phagocytic general method of action to be specifically related to cumulative charge from insertions placed on the SARS-CoV-2 spike surface in positions to bind efficiently by salt bridge formations; and from blasting the spike we display the NHL epitopes from which Biovacc-19 has been down-selected.
Item Type: | Article | ||||||
---|---|---|---|---|---|---|---|
Additional Information: | © The Author(s) 2020. Published by Cambridge University Press This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. | ||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||
Journal or Publication Title: | QRB Discovery | ||||||
ISSN: | 2633-2892 | ||||||
Language: | en | ||||||
Dates: |
|
||||||
Publisher License: | Creative Commons: Attribution 4.0 | ||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/112060 | ||||||
Publisher's version: | https://doi.org/10.1017/qrd.2020.8 |
Statistics
Actions (login required)
![]() |
Edit Item |